Bronchopulmonary Dysplasia: Clinical Management



The management of the infant with BPD is aimed at maintaining adequate gas exchange while at the same time limiting the progression of the lung damage. The challenge is that the supplemental oxygen and mechanical ventilation needed to maintain gas exchange are some of the key factors implicated in the pathogenesis of the lung damage (Chap.  79).


Neonatal Bronchopulmonary Dysplasia Clinical Management 

Suggested Reading

  1. AAP. Postnatal Corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330–8.CrossRefGoogle Scholar
  2. Aschner JL. New therapies for pulmonary hypertension in neonates and children. Pediatr Pulmonol Suppl. 2004;26:132–5.CrossRefPubMedGoogle Scholar
  3. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349: 959–67.CrossRefPubMedGoogle Scholar
  4. Atkinson SA. Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. J Nutr. 2001;131:942S–6.PubMedGoogle Scholar
  5. Bancalari E. Bronchopulmonary dysplasia. Semin Perinatol. 2003;8:1–92.Google Scholar
  6. Brunton JA, Saigal S, Atkinson S. Growth and body composition in infants with bronchopulmonary dysplasia up to 3 months corrected age: a randomized trial of a high-energy nutrient-enriched formula fed after hospital discharge. J Pediatr. 1998;133:340–5.CrossRefPubMedGoogle Scholar
  7. Buzzella B, Claure N, D’Ugard C, Bancalari E. A randomized controlled trial of two nasal continuous positive airway pressure levels after extubation in preterm infants. J Pediatr. 2014;164:46–51.CrossRefPubMedGoogle Scholar
  8. Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340:1005–10.CrossRefPubMedGoogle Scholar
  9. D’Angio CT, Maniscalco WM. Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies. Paediatr Drugs. 2004;6:303–30.CrossRefPubMedGoogle Scholar
  10. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010;98:111–7.CrossRefPubMedGoogle Scholar
  11. Greenough A. Update on patient-triggered ventilation. Clin Perinatol. 2001;28:533–46.CrossRefPubMedGoogle Scholar
  12. Grier DG, Halliday HL. Corticosteroids in the prevention and management of BPD. Semin Neonatol. 2003;8:83–91.CrossRefPubMedGoogle Scholar
  13. Kao LC, Durand DJ, McCrea RC, et al. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr. 1994;124:772–81.CrossRefPubMedGoogle Scholar
  14. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009;154(3):379–84.CrossRefPubMedGoogle Scholar
  15. O’Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104:15–21.CrossRefPubMedGoogle Scholar
  16. Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009;123:367–77.CrossRefPubMedGoogle Scholar
  17. Reyes Z, Tauscher M, Claure N. Randomized, controlled trial comparing pressure support (PS) + synchronized intermittent mandatory ventilation (SIMV) with SIMV in preterm infants. Pediatr Res. 2004;55:466A.CrossRefGoogle Scholar
  18. Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology. 2008;93:284–7.CrossRefPubMedGoogle Scholar
  19. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126:443–56.CrossRefPubMedPubMedCentralGoogle Scholar
  20. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–9.CrossRefPubMedCentralGoogle Scholar
  21. Tin W. Optimal oxygen saturation for preterm babies. Do we really know? Biol Neonate. 2004;85:319–25.CrossRefPubMedGoogle Scholar
  22. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340:1962–8.CrossRefPubMedGoogle Scholar
  23. Wardle AJ, Wardle R, Luyt K, et al. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Arch Dis Child. 2013;98:613–7.CrossRefPubMedGoogle Scholar
  24. Watterberg KL, Committee on Fetus and Newborn. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010;126:800–8.CrossRefPubMedGoogle Scholar
  25. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:e1–8.CrossRefGoogle Scholar
  26. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350: 1304–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of Neonatology, Department of PediatricsUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations